Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022

BUY
$144.95 - $152.29 $54.4 Million - $57.2 Million
375,508 Added 197.19%
565,941 $85.6 Million
Q2 2022

Oct 27, 2022

BUY
$83.14 - $145.99 $7.31 Million - $12.8 Million
87,881 Added 85.69%
190,433 $27.7 Million
Q2 2022

Aug 15, 2022

BUY
$83.14 - $145.99 $7.31 Million - $12.8 Million
87,881 Added 85.69%
190,433 $27.7 Million
Q1 2022

Oct 27, 2022

SELL
$110.08 - $142.92 $9.67 Million - $12.6 Million
-87,881 Reduced 46.15%
102,552 $12.2 Million
Q1 2022

May 13, 2022

BUY
$110.08 - $142.92 $2.2 Million - $2.85 Million
19,949 Added 24.15%
102,552 $12.2 Million
Q4 2021

Feb 14, 2022

BUY
$99.73 - $148.48 $4.01 Million - $5.98 Million
40,245 Added 95.01%
82,603 $11.4 Million
Q3 2021

Nov 15, 2021

BUY
$98.85 - $138.91 $4.19 Million - $5.88 Million
42,358 New
42,358 $5.88 Million

Others Institutions Holding BHVN

About Biohaven Pharmaceutical Holding Co Ltd.


  • Ticker BHVN
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 71,645,000
  • Market Cap $2.56B
  • Description
  • Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavege...
More about BHVN
Track This Portfolio

Track Morgan Stanley Portfolio

Follow Morgan Stanley and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.